​

Funding Round

Series B - Tempest Therapeutics

Series B - Tempest Therapeutics

Investment Firm

Overview

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.

Announced Date

Mar 28, 2018

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Versant Ventures

Versant Ventures

Versant Ventures is a early_stage_venture and late_stage_venture and post_ipo firm.

F-Prime Capital

F-Prime Capital

F-Prime Capital is a early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorForesite Capital
Participant InvestorLilly Asia Ventures
Participant InvestorF-Prime Capital
Participant InvestorVersant Ventures
Participant InvestorEight Roads Ventures

Round Details and Background

Tempest Therapeutics raised $70000000 on 2018-03-28 in Series B

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 28, 2018
Series B - Tempest Therapeutics
6-70.0M
Oct 05, 2011
Series A - Tempest Therapeutics
-5.0M
Apr 27, 2022
Post-IPO Equity - Tempest Therapeutics
2-15.0M

Recent Activity

There is no recent news or activity for this profile.